Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SILS Clear all
Recruiting Phase 2 Interventional

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564
View directory record Official record
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

NCT03499795
View directory record Official record
Conditions
Anal Neoplasm
Interventions
VGX-3100, CELLECTRA™ 5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 25, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Activating Collaborative CIS Support Via Targeted Provider Mailing

NCT00873288
View directory record Official record
Conditions
Precancerous Condition
Interventions
Usual care mailing intervention, CIS support mailing intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 25, 2026, 4:08 AM EDT
Completed No phase listed Observational

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

NCT00695422
View directory record Official record
Conditions
Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions
polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy
Genetic · Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy

NCT00981604
View directory record Official record
Conditions
Cholelithiasis, Biliary Dyskinesia
Interventions
SILS, Standard Laparoscopic Cholecystectomy
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Appendectomy

NCT00981136
View directory record Official record
Conditions
Appendicitis
Interventions
Single Incision Laparoscopic Appendectomy, 3 port laparoscopic appendectomy
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Month to 18 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

NCT00066430
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
infrared photocoagulation therapy, Infrared Coagulator
Procedure · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 25, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional Results available

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03197025
View directory record Official record
Conditions
Human Papillomavirus, HPV-16, High Grade Squamous Intraepithelial Lesion
Interventions
Aldesleukin, E6 T Cell Receptor (TCR)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

NCT00703196
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
folic acid, placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

NCT00550589
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
Drug · Genetic · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)

NCT00596258
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
A-007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Tucson, Arizona • Costa Mesa, California • Boynton Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2009 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

NCT02481414
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
PepCan, Candin®
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 25, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Results available

Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis

NCT00997516
View directory record Official record
Conditions
Appendicitis
Interventions
SILS appendectomy, conventional laparoscopic appendectomy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

NCT00001073
View directory record Official record
Conditions
HIV Infections, Cervix, Dysplasia
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Early Phase 1 Interventional Results available

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

NCT03196180
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia
Interventions
Imiquimod, Topical Fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 25, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03937791
View directory record Official record
Conditions
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
Interventions
E7 T Cell Receptor (TCR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

NCT00622440
View directory record Official record
Conditions
Anus Neoplasms
Interventions
AIJP (Arnebia Indigo Jade Pearl), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 25, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

NCT06075264
View directory record Official record
Conditions
Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions
Artesunate ointment, Placebo ointment
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 25, 2026, 4:08 AM EDT
Completed Not applicable Interventional

The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia

NCT00653146
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Mindfulness-Based Stress Reduction, Healthy Lifestyles
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 25, 2026, 4:08 AM EDT
Completed No phase listed Observational Results available

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

NCT04276935
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 25, 2026, 4:08 AM EDT